Pathoma Ch 4,5, 16, 17 (Hemostasis, RBC, Breast, CNS) Flashcards
4. Hemostasis and Related D/o 5. RBC D/o 16. Breast 17. CNS (155 cards)
Distinguish primary and secondary hemostasis
Primary hemostasis = formation of weak plt plug
-involves plt, fibrin
Secondary hemostasis = use of coagulation cascade to stabilize plt plug
First thing to happen after BV wall damage
(a) 2 mediators
BV wall damage => Immediate reflexive vasoconstriction
a) Mediated by both neural impulse and endothelin (from endothelial cells
Differentiate receptors/factors used for plt adhesion and plt aggregation
Steps of primary hemostasis (forming weak plt plug): vasoconstriction, plt adhesion, plt degranulation, finally plt aggregation
Plt aggregation = plts bind to subendothelial collagen by binding to vWF via GP1b receptor
Then plt aggregation for plts to clump together mediated by Gp3a2b receptor using fibrinogen
Name the 2 key molecules released by platelet degranulation in primary hemostasis
Plt degranulation (after adhesion, before aggregation) releases
- ADP (from plt dense granules) that promotes exposure of Gp2b3a receptors
- TXA2 (from plt COX) that stimulates plts aggregation
2 places where vWF is made/released from
- Weibel-Palade bodies of endothelial cells (main source)
- this is why ADH (that stimulates Weibel-Palade body release of vWF) is used in the tx of vWD - Alpha-granules of plts
Differentiate the types of bleeding seen in d/o of primary vs. secondary hemostasis
Primary hemostasis = formation of weak platelet plug with plts and fibrin
-d/o => mucosal and skin bleeding = epistaxis, hemoptysis, GI bleed, hematuria, petechiae, purpura
Secondary hemostasis = stabilization of plt plug via coagulation cascade
-d/o (coag factor deficiencies) => deep tissue bleeds in joints and muscles, also rebleeding after surgical procedures (classically wisdom teeth)
Differentiate ecchymoses, purpura, and petechiae
All skin (superficial) bleeds, differentiated by size
Ecchymoses = superficial bleed over 1cm
Purpura: over 3mm
Petechiae: 1-2mm (indicative of thrombocytopenia
Clinical sign that can help distinguish thrombocytopenia from poor quality of plts
Petechiae (1-2mm skin bruises) indicate thrombocytopenia (low number of plts)
-while petechiae are not seen in d/o of plt quality (usually d/o of plt receptors such as Gp1b needed for adhesion, Gp2b3a for aggregation
Bone marrow biopsy expected in ITP
Immune thrombocytopenic purpura (IgG against plts)- see megakaryocyte hyperplasia b/c megakaryocytes trying to compensate for low plts
Name 2 general categories of d/o of primary hemostasis
D/o primary hemostasis = d/o of plts
- Immune thrombocytopenic purpura (ITP) = IgG against plts
- Microangiopathic hemolytic anemia (includes HUS and TTP) = pathologic formation of plt microthrombi in small vessels 2/2 either E. Coli O157:H7 or ADAMTS13 deficiency
Differentiate acute and chronic ITP
Acute ITP seen in children s/p viral illness or vaccination, get self-limited disease
Chronic form in adults (often women of childbearing age, aka same ppl who get AI d/o)
Plt count and PT/PTT values expected in
(a) ITP
(b) HUS
(c) TTP
(a) ITP: reduced plts (2/2 presence of anti-plt IgG so plts destroyed in spleen), PT/PTT normal b/c coagulation cascade (clotting factors) are unaffected
(b) HUS and TTP = microangiopathic hemolytic anemias (meaning pathology of the small HVs that causes hemolytic anemia): reduced plt count (b/c plts used up in microthrombi) and normal PT/PTT
Explain how IVIG aids in the tx of ITP
IVIG = intravenous immunoglobulin
Basically give the spleen another immunoglublin to worry about, so it has a decreased capacity to destroy IgG marked plts
-uesd as very acute/transient therapy during symptomatic bleed
Give 2 mechanisms by which splenectomy treats ITP
ITP = IgG against antibodies
- These antibodies are produced by the spleen
- The spleen is where the plts are destroyed once they become bound to the IgGs
So splenectomy removes both the source of the Ab and the site of plt degradation
HUS vs. TTP
(a) Etiology
(b) MC organ system involved
HUS and TTP are both microangiopathic hemolytic anemias (pathology of small BVs where plt microthrombi are produced causing hemolytic anemia)
HUS = hemolytic uremic syndrome
(a) Etiology = infection w/ E. Coli 0157:H7
(b) MC involves kidney (umm hence uremic in name)
TTP = thrombotic thrombocytopenic purpura
(a) Etiology = deficiency in ADAMTS13 = enzyme needed to cleave vWF into active form => plts abnormal adhere and form microthrombi
(b) MC see CNS abnormalities (thrombi involving vessels of the CNS)
Name the activating substance of the intrinsic and extrinsic pathways of the coagulation cascade
Intrinsic pathway (12 –> 11 –> 9 –> 8 –> X) activates by tissue thromboplastic factor
Extrinsic pathway (7 –> X) activated by subendothelial collagen
Hemophilia A
(a) What is it?
(b) Etiology
(c) Lab findings
Hemophilia A
(a) X-linked recessive deficiency in factor VIII (A ‘eight’)
(b) Etiology: usually X-linked recessive but can be 2/2 de novo mutation
(c) Normal bleeding time (b/c primary hemostasis of weak plt plug is normal, normal plt count), prolonged PTT w/ normal PT
Hemophilia A vs. hemophilia B
Hemophilia A = deficiency in factor VIII
Hemophilia B = deficiency in factor IX (just one back in the cascade): affects same pathway (intrinsic pathway) => both have the same findings of
- prolonged PTT, normal PT
- normal bleeding time b/c plts unaffected
How to differentiate hemophilia A from acquired coagulation factor inhibitor
Hemophilia A = deficiency in factor VIII
Acquired (autoimmune usually) inhibition of factor VIII (ex: IgG against factor VIII)
Same clinical and lab findings (deep joint bleeds and prolonged PTT), but different mixing study
-mixing study (mix pt blood w/ normal plasma): PTT corrects in hemophilia A, PTT does NOT correct in acquired inhibitor (b/c there’s an inhibitor present…)
von Willebrand disease: Lab findings
von Willebrand disease = deficiency in vWF, factor that binds to subendothelial collagen in damaged endothelium and binds plts via receptor Gp1b
Lab findings: prolonged bleeding time (b/c plt activity is impacted), prolonged PTT b/c factor VIII needs vWF to be stable
Abnormal ristocetin test
Ristocetin induces plt agglutination by causing vWF to bind to plt Gp1b (receptor for adhesion).
In vonWillebrand disease, ristocetin won’t cause agglutination (b/c no vWF present) => abnormal test
Explain why the following populations may be deficient in vitamin K
(a) Newborns
(b) Long term abx takers
(c) Malabsorption
(a) Newborns have immature gut flora
- hence why nerborns are prophylactically given vitK injection at birth to prevent hemorrhagic disease of newborn
(b) Long term abx kills the gut flora that normal synthesize vitK
(c) Malabsorption of fat-soluble vitamins (ADEK)
Epoxide reductase function
(a) Effect of inhibition
Epoxide reductase is the liver enzyme that activates vitamin K
(a) When vitK isn’t active, factors X, IX, VII, II, protein C and S don’t get gamma carboxylated => factors aren’t active
What value is followed to monitor effect of liver failure on coagulation
Follow PT: tracks extrinsic pathway (factor VII –> X) and common pathway
- factor VII produced in the liver, so PT is pretty specific
- vs. PTT which counts on factors 12, 11, 9, and 8